It was in April 2000 that we launched this website, replacing the newsletter I had written for patients at the CML outpatients clinic at Hammersmith Hospital London, on my return from the phase ll trial in the US.
I was so amazed that I had survived what was a dire prognosis that I had wanted to reach as many people as possible with the news that STI571 (imatinib) was continuing to amaze doctors and patients enrolled on the phase l and ll trials in the US, so much so that expanded access trials were to be set up in UK and Europe.
From this small beginning, over 13 years ago, we have seen an amazing transformation in the prognosis of CML.
I hope that we will see a cure for CML within the next 5 to 10 years, and that everyone diagnosed with Ph+CML will be able to access the right therapy as well as effective monitoring by RT Q-PCR, no matter where they live or who they are.
Sandy